M
MitoImmune Therapeutics
Biotech innovator developing breakthrough therapeutics targeting mitochondrial dysfunction to treat necrotic and inflammatory diseases
About MitoImmune Therapeutics
MitoImmune Therapeutics Inc. is a biotech company focused on drug discovery and development, leveraging proprietary technology to target mitochondria for creating potential breakthrough therapeutics. The company aims to increase healthy lifespan by addressing mitochondrial dysfunction, which is linked to necrotic and inflammatory diseases. MitoImmune collaborates with leading experts in mitochondria biology and medicine to identify new treatments that enhance mitochondrial function and improve patient quality of life. The company serves a global market, targeting millions of patients suffering from mitochondrial-related conditions. Its business model involves extensive research and development, followed by clinical trials and eventual commercialization of successful therapeutics. Revenue is generated through the sale of these therapeutics, partnerships, and potentially licensing its proprietary technology.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Sep 2023 | $4.4M | $115M | KGround Partners · BMI Korea | ↗ |
| SERIES B✓Equity / VC | Apr 2021 | $23M | $92M | BNH Investment · SL Investment | ↗ |
Growth signals
Latest recorded traffic for MitoImmune Therapeutics is 3K monthly website visits, down 6.3% over the last three months. MitoImmune Therapeutics's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
MitoImmune Therapeutics in the Seoul ecosystem
The MitoImmune Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
KB Investment
Korea Development Bank
SL Investment- BIBNH Investment
Series B and later2 investors entered at this stage
KGround Partners
BMI Korea
Other known investors2 additional known investors
Aju IB Investment
Quantum Ventures Korea
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MitoImmune Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MitoImmune Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








